EP1109548A4 - Utilisation de procedes et de compositions a base de tocotrienols pour traiter et prevenir les maladies osseuses - Google Patents

Utilisation de procedes et de compositions a base de tocotrienols pour traiter et prevenir les maladies osseuses

Info

Publication number
EP1109548A4
EP1109548A4 EP99930883A EP99930883A EP1109548A4 EP 1109548 A4 EP1109548 A4 EP 1109548A4 EP 99930883 A EP99930883 A EP 99930883A EP 99930883 A EP99930883 A EP 99930883A EP 1109548 A4 EP1109548 A4 EP 1109548A4
Authority
EP
European Patent Office
Prior art keywords
tocotrienols
compositions
treating
methods
bone diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99930883A
Other languages
German (de)
English (en)
Other versions
EP1109548A1 (fr
Inventor
Ronald H Lane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipogenics Inc
Original Assignee
Lipogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipogenics Inc filed Critical Lipogenics Inc
Publication of EP1109548A1 publication Critical patent/EP1109548A1/fr
Publication of EP1109548A4 publication Critical patent/EP1109548A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP99930883A 1998-07-08 1999-07-08 Utilisation de procedes et de compositions a base de tocotrienols pour traiter et prevenir les maladies osseuses Withdrawn EP1109548A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9210198P 1998-07-08 1998-07-08
US92101P 1998-07-08
PCT/US1999/015452 WO2000002553A1 (fr) 1998-07-08 1999-07-08 Utilisation de procedes et de compositions a base de tocotrienols pour traiter et prevenir les maladies osseuses

Publications (2)

Publication Number Publication Date
EP1109548A1 EP1109548A1 (fr) 2001-06-27
EP1109548A4 true EP1109548A4 (fr) 2001-12-12

Family

ID=22231570

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99930883A Withdrawn EP1109548A4 (fr) 1998-07-08 1999-07-08 Utilisation de procedes et de compositions a base de tocotrienols pour traiter et prevenir les maladies osseuses

Country Status (6)

Country Link
EP (1) EP1109548A4 (fr)
JP (1) JP2002520280A (fr)
CN (1) CN1316903A (fr)
AU (1) AU4732499A (fr)
ID (1) ID28460A (fr)
WO (1) WO2000002553A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020076470A1 (en) 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
US8669282B2 (en) * 2000-10-31 2014-03-11 Hill's Pet Nutrition, Inc. Companion animal compositions including lipoic acid and methods of use thereof
WO2002055071A1 (fr) * 2001-01-15 2002-07-18 Kgk Synergize Compositions et methodes de regulation du taux de lipoproteines et de l'hypercholesterolemie au moyen de limonoides, de flavonoides et de tocotrienols
CN1713915A (zh) * 2001-10-10 2005-12-28 法马西亚意大利公司 用甾族化合物预防和治疗骨丢失的方法
WO2003092666A1 (fr) * 2002-05-01 2003-11-13 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Agents de renforcement de tissus contenant du calcium et utilisation correspondante
FR2841472B1 (fr) * 2002-06-28 2006-02-24 Agronomique Inst Nat Rech Composition nutritionnelle ou therapeutique contenant le compose hesperidine ou l'un de ses derives
FR2899106B1 (fr) * 2002-11-19 2015-04-24 Engelhard Lyon Utilisation d'une substance pour limiter et/ou prevenir la modification d'au moins un parametre biologique modifie au cours d'une irradiation
TW200524892A (en) * 2003-09-24 2005-08-01 Glaxo Group Ltd Calcilytic compounds
WO2006024096A1 (fr) * 2004-08-31 2006-03-09 Chemgenex Pharmaceuticals Limited Procédé servant à moduler l'ostéoclastogénèse
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
EP2452670A1 (fr) * 2004-10-01 2012-05-16 Ramscor, Inc. Compositions de médicaments à libération prolongée parfaitement implantable
WO2006071919A2 (fr) 2004-12-29 2006-07-06 Hill's Pet Nutrition, Inc. Methodes permettant d'inhiber un declin des facultes d'apprentissage et/ou de la memoire chez les animaux
CN101262780B (zh) 2005-07-14 2013-04-24 希尔氏宠物营养品公司 一种延长动物生命的方法
US8288369B2 (en) * 2006-06-27 2012-10-16 University Of South Florida Delta-tocotrienol treatment and prevention of pancreatic cancer
JP5337405B2 (ja) 2007-09-17 2013-11-06 ザ・ホスピタル・フォー・シック・チルドレン ゴーシェ病の治療方法
AU2016200420B2 (en) * 2008-12-30 2017-03-02 Hill's Pet Nutrition, Inc. Companion animal compositions including lipoic acid and methods of use thereof
WO2010104079A1 (fr) * 2009-03-13 2010-09-16 明治乳業株式会社 Composition destinée à réduire le risque de fractures osseuses et/ou à prévenir des fractures osseuses
NL2008294C2 (en) * 2011-05-20 2013-08-19 Friesland Brands Bv Food composition comprising vitamin k and saturated fat.
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
CN105744835A (zh) 2013-07-22 2016-07-06 俄亥俄州国家创新基金会 用于减少热潮红发生的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61183206A (ja) * 1985-02-09 1986-08-15 Lion Corp 化粧料

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574063A (en) * 1989-10-12 1996-11-12 Perricone; Nicholas V. Method and compositions for topical application of ascorbic acid fatty acid esters for treatment and/or prevention of skin damage

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61183206A (ja) * 1985-02-09 1986-08-15 Lion Corp 化粧料

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 198639, Derwent World Patents Index; AN 1986-255366, XP002180150 *
See also references of WO0002553A1 *

Also Published As

Publication number Publication date
WO2000002553A1 (fr) 2000-01-20
ID28460A (id) 2001-05-24
EP1109548A1 (fr) 2001-06-27
AU4732499A (en) 2000-02-01
JP2002520280A (ja) 2002-07-09
CN1316903A (zh) 2001-10-10

Similar Documents

Publication Publication Date Title
IL142132A0 (en) Methods and compositions for treating receptor mediated diseases
EP1109548A4 (fr) Utilisation de procedes et de compositions a base de tocotrienols pour traiter et prevenir les maladies osseuses
EP0973513A4 (fr) Compositions et methodes pour traiter les etats associes a un deficit osseux
IL142906A0 (en) Methods and compositions for treating or preventing peripheral neuropathies
HUP0201436A2 (en) Methods and compositions for treating solid tumors
AUPQ127399A0 (en) Compositions and methods for treating or preventing osteoporosis
HK1048949A1 (en) Method and composition for the treatment of scars
EP1217963A4 (fr) Dispositifs et procedes de traitement de tissu
AU6872498A (en) Method and composition for skin treatment
AU2327599A (en) Compositions and methods for treating autoimmune diseases
EP1088333A4 (fr) Compositions et procedes inhibant la resorption osseuse
AU5774699A (en) Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
IL124650A0 (en) Methods and therapeutic compositions for treating cancer
EP1051169A4 (fr) Composes, compositions et methodes de traitement ou de prevention d'infections pneumovirales et de maladies associees
IL141426A0 (en) Compositions and methods for the treatment of tumor
IL143212A0 (en) Compositions and methods for the treatment of tumor
AU5594398A (en) Methods and compositions for preventing and treating bone loss
EP1089731A4 (fr) Compositions et methodes de traitement d'une cholesterolemie elevee
AU5791698A (en) Methods and compositions for preventing and treating bone loss
SG65766A1 (en) Composition for preventing and treating gingival diseases
EP1096927A4 (fr) Composition pour le traitement du stress
EP1089750A4 (fr) Compositions et procedes permettant d'inhiber la resorption d'un os
AU5169200A (en) Methods and compositions for treating breakthrough pain
AU5097099A (en) Methods and compositions for cancer treatment
HUP0300043A3 (en) Method and composition for the treatment of pain

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010426

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20011026

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

18D Application deemed to be withdrawn

Effective date: 20030203

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

R18D Application deemed to be withdrawn (corrected)

Effective date: 20030201